All In Biotech

Drug Trial Radar · NCT05912517

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Dec 20, 2023

Primary completion

Aug 5, 2027

Study completion Oct 8, 2029

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jun 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the effectiveness of nipocalimab when compared to placebo in decreasing the risk of fetal anemia (a condition in which a baby's red blood cell volume falls below normal levels while the baby is developing in the womb) with live neonates in pregnant participants at risk for severe hemolytic disease of the fetus and newborn.

Conditions

  • Hemolytic Disease of the Fetus and Newborn

Interventions

  • NipocalimabDrug

    Nipocalimab will be administered as an intravenous infusion.

  • PlaceboDrug

    Placebo will be administered as an intravenous infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Pregnancies That did not Result in Fetal Loss, Intrauterine Transfusion (IUT), Hydrops Fetalis, or Neonatal DeathTime frame: From randomization in the study through 4 weeks of age or 41 weeks Postmenstrual Age (PMA) during neonatal period, whichever is later

Locations

69 sites in 18 countries. Site status is shown where the registry gives one.

  • University of California at San Diego

    La Jolla, California · Recruiting

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California · Recruiting

  • UC Davis School of Medicine

    Sacramento, California · Recruiting

  • Childrens Hospital Colorado

    Aurora, Colorado · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Advocate Children's Hospital

    Park Ridge, Illinois · Recruiting

  • Riley Children s Hospital

    Indianapolis, Indiana · Suspended

  • University of Iowa

    Iowa City, Iowa · Recruiting

  • University of Kentucky Medical Center

    Lexington, Kentucky · Recruiting

  • Johns Hopkins Hospital

    Baltimore, Maryland · Recruiting

  • Boston Childrens Hospital

    Boston, Massachusetts · Recruiting

  • Midwest Fetal Care Center

    Minneapolis, Minnesota · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • University of North Carolina (UNC) - School of Medicine

    Chapel Hill, North Carolina · Recruiting

  • University of Cincinnati

    Cincinnati, Ohio · Recruiting

  • Oregon Health and Science University

    Portland, Oregon · Recruiting

  • Lehigh Valley Hospital

    Allentown, Pennsylvania · Recruiting

  • University of Texas Dell Medical School Department of Women's Health

    Austin, Texas · Recruiting

  • University Of Texas Medical Branch At Galveston

    Galveston, Texas · Recruiting

  • Intermountain Medical Center

    Murray, Utah · Recruiting

  • Macon & Joan Brock Virginia Health Sciences at Old Dominion University

    Norfolk, Virginia · Recruiting

  • Seattle Children's Hospital

    Seattle, Washington · Recruiting

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina · Recruiting

  • Hospital Privado Universitario De Cordoba

    Córdoba, Argentina · Recruiting

  • Mater Hospital Brisbane

    South Brisbane, Australia · Recruiting

  • Liverpool Hospital

    Sydney, Australia · Recruiting

  • Medizinische Universitaet Graz

    Graz, Austria · Recruiting

  • Medizinische Universitaet Wien

    Vienna, Austria · Recruiting

  • C.H.U. Brugmann

    Brussels, Belgium · Recruiting

  • Universitair Ziekenhuis Leuven

    Leuven, Belgium · Recruiting

  • Faculdade de Medicina Universidade Federal de Minas Gerais

    Belo Horizonte, Brazil · Recruiting

  • Hospital das Clinicas - UFG

    Goiânia, Brazil · Recruiting

  • Instituto de Medicina Integral Professor Fernando Figueira

    Recife, Brazil · Recruiting

  • IDOR - Regional Rio de Janeiro

    Rio de Janeiro, Brazil · Recruiting

  • Hospital Das Clinicas Da Faculdade De Medicina Da USP

    São Paulo, Brazil · Recruiting

  • BC Women's Hospital University of British Columbia

    Vancouver, British Columbia, Canada · Recruiting

  • Mount Sinai Hospital

    Toronto, Ontario, Canada · Recruiting

  • Centre Hospitalier Sainte Justine

    Montreal, Quebec, Canada · Recruiting

  • McGill University Health Centre

    Montreal, Quebec, Canada · Recruiting

  • Hospices Civils de Lyon - Groupement Hospitalier Est - Hopital Femme Mere Enfant

    Bron, France · Recruiting

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.